HIMS vs. AMWL: Which Telehealth Stock Is the Better Investment Now?

Core Insights - Digital healthcare is evolving with distinct approaches represented by Hims & Hers Health, Inc. (HIMS) and American Well Corporation (AMWL), focusing on consumer-first and enterprise platforms respectively [1][2] Company Overview - HIMS operates a subscription-based platform connecting consumers to healthcare providers for telehealth consultations and wellness support, while AMWL provides technology infrastructure for health systems and plans to deliver hybrid care [1][2] - HIMS is expanding into various health categories including weight management, menopause, and testing, while AMWL is refocusing on enterprise clients and targeting positive cash flow by 2026 [6][10] Stock Performance & Valuation - HIMS has underperformed with a stock decline of 63.1% over the past year, while AMWL's stock declined by 46.6% [3] - HIMS has a forward price-to-sales (P/S) ratio of 1.3X, below its five-year median of 2.7X, while AMWL's forward P/S is at 0.4X, below its five-year median of 1.6X [5] Growth Strategies - HIMS is investing in AI, diagnostics, and acquisitions to enhance its platform and expand internationally, with recent agreements to acquire companies in Australia, Japan, Germany, and the U.K. [8][9] - AMWL has streamlined operations and focused on its core platform, strengthening recurring revenue and aligning with demand for consolidated digital health infrastructure [10][12] Financial Projections - HIMS' earnings per share (EPS) for 2026 is projected to remain flat year-over-year, while AMWL's loss per share is expected to improve by 46.8% from 2025 [14][16] - The average price target for HIMS is $25.54, indicating a potential increase of 65.2%, while AMWL's average price target is $6.25, suggesting a 15.3% increase [18][19] Investment Outlook - HIMS is viewed as better positioned for long-term growth despite recent underperformance, with a focus on expanding its consumer platform and enhancing engagement [21][22] - AMWL is advancing its enterprise strategy but faces revenue decline, making HIMS a more compelling opportunity for investors seeking telehealth exposure [22][23]